Federal Register / Vol. 69, No. 208 / Thursday, October 28, 2004 / Rules and Regulations 62809

of it may be obtained from the Rules 

Docket at the location provided under 

the caption ADDRESSES.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation 

safety, Incorporation by reference, 

Safety.

Adoption of the Amendment

■ Accordingly, pursuant to the authority 

delegated to me by the Administrator, 

the Federal Aviation Administration 

amends part 39 of the Federal Aviation 

Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS 

DIRECTIVES

■ 1. The authority citation for part 39 

continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

■ 2. Section 39.13 is amended by adding 

the following new airworthiness 

directive:

2004–22–08 Bombardier, Inc. (Formerly 

Canadair): Amendment 39–13836. 

Docket 2003–NM–158–AD.

Applicability: All Model CL–600–2B19 

(Regional Jet Series 100 & 440) airplanes, 

certificated in any category. 

Compliance: Required as indicated, unless 

accomplished previously. 

To prevent disconnection of an air supply 

duct, which, if combined with failure of a 

bulkhead check valve, could result in rapid 

depressurization of the airplane, accomplish 

the following: 

Service Information References 

(a) Paragraphs (a)(1), (a)(2), (a)(3), and (a)(4) 

of this AD pertain to the service information 

referenced in this AD. 

(1) The term service bulletin, as used in 

this AD, means the Accomplishment 

Instructions of Bombardier Alert Service 

Bulletin A601R–21–053, Revision ‘A,’ dated 

January 28, 2003; and Bombardier Alert 

Service Bulletin A601R–21–054, dated 

November 8, 2001; as applicable. 

(2) Although the service bulletins 

referenced in this AD specify to submit 

certain information to the manufacturer, this 

AD does not include such a requirement. 

(3) Bombardier Alert Service Bulletin 

A601R–21–054, dated November 8, 2001, 

recommends sending all damaged check 

valves to the manufacturer for analysis; 

however, this AD does not include that 

requirement. 

(4) Accomplishment of the actions 

specified in Bombardier Alert Service 

Bulletin A601R–21–053, dated November 8, 

2001, before the effective date of this AD is 

considered acceptable for compliance with 

the applicable actions specified in this AD. 

Repetitive Inspections/Related Corrective 

Actions 

(b) Within 500 flight hours after the 

effective date of this AD: Do the detailed 

inspections and related corrective actions 

required by paragraphs (b)(1) and (b)(2) of 

this AD, per the applicable service bulletin. 

(1) For airplanes having bulkhead check 

valves with part number (P/N) 92E20–3/–4, 

as identified in Bombardier Alert Service 

Bulletin A601R–21–054, dated November 8, 

2001: Inspect the left- and right-hand 

bulkhead check valves for damage (cracking, 

breakage). If any damage is found, before 

further flight, replace the damaged valve. 

Repeat the inspection at intervals not to 

exceed 4,000 flight hours. 

(2) For airplanes having serial numbers 

7003 through 7067 inclusive, and 7069 

through 7477 inclusive: Inspect the left- and 

right-hand air supply ducts of the rear 

bulkhead for damage (tearing, delamination, 

or cracking). If any damage is found, before 

further flight, either rework or replace the 

damaged air supply duct, which ends the 

inspections for that air supply duct only. If 

no damage is found, repeat the inspection 

thereafter at intervals not to exceed 500 flight 

hours until accomplishment of paragraph (c) 

of this AD.

Note 1: For the purposes of this AD, a 

detailed inspection is defined as: ‘‘An 

intensive visual examination of a specific 

structural area, system, installation, or 

assembly to detect damage, failure, or 

irregularity. Available lighting is normally 

supplemented with a direct source of good 

lighting at intensity deemed appropriate by 

the inspector. Inspection aids such as mirror, 

magnifying lenses, etc., may be used. Surface 

cleaning and elaborate access procedures 

may be required.

Terminating Action for Repetitive 

Inspections of Air Supply Ducts 

(c) Except as required by paragraph (b)(2) 

of this AD, for airplanes having serial 

numbers 7003 through 7067 inclusive, and 

7069 through 7477 inclusive: Within 5,000 

flight hours after the effective date of this AD, 

either rework or replace the left- and righthand air ducts, as applicable, per the 

applicable service bulletin. Accomplishment 

of this paragraph ends the repetitive 

inspections required by paragraph (b)(2) of 

this AD. 

Alternative Methods of Compliance 

(d) In accordance with 14 CFR 39.19, the 

Manager, New York Aircraft Certification 

Office, FAA, is authorized to approve 

alternative methods of compliance for this 

AD. 

Incorporation by Reference 

(e) Unless otherwise specified in this AD, 

the actions shall be done in accordance with 

Bombardier Alert Service Bulletin A601R–

21–053, Revision ‘A,’ dated January 28, 2003; 

and Bombardier Alert Service Bulletin 

A601R–21–054, dated November 8, 2001; as 

applicable. This incorporation by reference 

was approved by the Director of the Federal 

Register in accordance with 5 U.S.C. 552(a) 

and 1 CFR part 51. Copies may be obtained 

from Bombardier, Inc., Canadair, Aerospace 

Group, P.O. Box 6087, Station Centre-ville, 

Montreal, Quebec H3C 3G9, Canada. Copies 

may be inspected at the FAA, Transport 

Airplane Directorate, 1601 Lind Avenue, 

SW., Renton, Washington; or at the FAA, 

New York Aircraft Certification Office, 1600 

Stewart Avenue, suite 410, Westbury, New 

York; or at the National Archives and 

Records Administration (NARA). For 

information on the availability of this 

material at NARA, call (202) 741–6030, or go 

to: http://www.archives.gov/federal_register/

code_of_federal_regulations/

ibr_locations.html.

Note 2: The subject of this AD is addressed 

in Canadian airworthiness directive CF–

2003–05, dated February 4, 2003.

Effective Date 

(f) This amendment becomes effective on 

December 2, 2004.

Issued in Renton, Washington, on October 

18, 2004. 

Kalene C. Yanamura, 

Acting Manager, Transport Airplane 

Directorate, Aircraft Certification Service.

[FR Doc. 04–24028 Filed 10–27–04; 8:45 am] 

BILLING CODE 4910–13–P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration 

14 CFR Part 61

[Docket No. FAA–2002–11666; Amendment 

No. 61–111] 

RIN 2120–AH76

Picture Identification Requirements

AGENCY: Federal Aviation 

Administration (FAA), DOT.

ACTION: Final rule; correction.

SUMMARY: This document corrects an 

amendment number in the final rule 

published in the Federal Register on 

October 28, 2002. That rule revised the 

pilot certificate regulations requiring a 

person to carry a photo identification 

acceptable to the FAA Administrator 

when exercising the privileges of a pilot 

certificate.

DATES: Effective Date: This correction is 

effective on October 28, 2004.

FOR FURTHER INFORMATION CONTACT: John 

D. Lynch, telephone (202) 267–3844. 

Correction 

In the final rule FR Doc. 02–27411 

published on October 28, 2002 (67 FR 

65858) make the following correction: 

1. On page 65858, in column 1, in the 

heading section of the rule , beginning 

on line 4 of the heading, correct 

‘‘Amendment No. 61–107’’ to read 

‘‘Amendment No. 61–111.’’

62810 Federal Register / Vol. 69, No. 208 / Thursday, October 28, 2004 / Rules and Regulations 

Issued in Washington, DC on October 22, 

2004. 

Anthony F. Fazio, 

Director, Office of Rulemaking.

[FR Doc. 04–24141 Filed 10–27–04; 8:45 am] 

BILLING CODE 4910–13–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES

Food and Drug Administration

21 CFR Part 14

Advisory Committee: Change of Name 

and Function; Technical Amendment

AGENCY: Food and Drug Administration, 

HHS.

ACTION: Final rule; technical 

amendment.

SUMMARY: The Food and Drug 

Administration (FDA) is amending the 

standing advisory committees’

regulations to change the name and 

function of the Biological Response 

Modifiers Advisory Committee. This 

action is being taken to reflect changes 

made to the charter for this advisory 

committee.

DATES: This rule is effective October 28, 

2004.

FOR FURTHER INFORMATION CONTACT:

Theresa Green, Advisory Committee 

Oversight Management Staff (HF–4), 

Food and Drug Administration, 5600 

Fishers Lane, Rockville, MD 20857, 

301–827–1220.

SUPPLEMENTARY INFORMATION: FDA is 

announcing that the name of the 

Biological Response Modifiers Advisory 

Committee, which was established on 

October 28, 1988, has been changed. 

The name ‘‘Cellular, Tissue and Gene 

Therapies Advisory Committee’’ more 

accurately describes the subject areas for 

which the committee is responsible. The 

committee reviews and evaluates 

available data relating to the safety, 

effectiveness, and appropriate use of 

human cells, human tissues, gene 

transfer therapies, and 

xenotransplantation products which are 

intended for transplantation, 

implantation, infusion, and transfer in 

the prevention and treatment of a broad 

spectrum of human diseases, and in the 

reconstruction, repair or replacement of 

tissues for various conditions. The 

Committee also considers the quality 

and relevance of FDA’s research 

program which provides scientific 

support for the regulation of these 

products, and makes appropriate 

recommendations to the Commissioner 

of Food and Drugs.

The Biological Response Modifiers 

Advisory Committee name was changed 

and its functions expanded in the 

charter renewal dated October 28, 2004. 

FDA is revising 21 CFR 14.100(b)(2) to 

reflect these changes. In this document, 

FDA is hereby formally changing the 

name and the function of the committee 

by revising 21 CFR 14.100(b)(2).

Publication of this final rule 

constitutes a final action on this change 

under the Administrative Procedure 

Act. Under 5 U.S.C. 553(b)(B) and (d) 

and 21 CFR 10.40(d) and (e), the agency 

finds good cause to dispense with notice 

and public procedure and to proceed to 

an immediately effective regulation. 

Such notice and procedures are 

unnecessary and are not in the public 

interest, because the final rule is merely 

codifying the new name and expanded 

function of the advisory committee to 

reflect the current committee charter.

List of Subjects in 21 CFR Part 14

Administrative practice and 

procedure, Advisory committees, Color 

additives, Drugs, Radiation protection.

■ Therefore, under the Federal Food, 

Drug, and Cosmetic Act and under 

authority delegated to the Commissioner 

of Food and Drugs, 21 CFR part 14 is 

amended as follows:

PART 14—PUBLIC HEARING BEFORE 

A PUBLIC ADVISORY COMMITTEE

■ 1. The authority citation for 21 CFR 

part 14 continues to read as follows:

Authority: 5 U.S.C. App. 2; 15 U.S.C. 

1451–1461, 21 U.S.C. 41–50, 141–149, 321–

394, 467f, 679, 821, 1034; 28 U.S.C. 2112; 42 

U.S.C. 201, 262, 263b, 264; Pub. L. 107–109; 

Pub. L. 108–155.

■ 2. Section 14.100 is amended by 

revising the heading of paragraph (b)(2) 

and paragraph (b)(2)(ii) to read as 

follows:

§ 14.100 List of standing advisory 

committees.

* * * * *

(b) * * *

(2) Cellular, Tissue and Gene 

Therapies Advisory Committee.

* * * * *

(ii) Function: Reviews and evaluates 

available data relating to the safety, 

effectiveness, and appropriate use of 

human cells, human tissues, gene 

transfer therapies and 

xenotransplantation products which are 

intended for transplantation, 

implantation, infusion, and transfer in 

the prevention and treatment of a broad 

spectrum of human diseases and in the 

reconstruction, repair or replacement of 

tissues for various conditions. The 

Committee also considers the quality 

and relevance of FDA’s research 

program which provides scientific 

support for the regulation of these 

products, and makes appropriate 

recommendations to the Commissioner 

of Food and Drugs.

* * * * *

Dated: October 21, 2004.

Sheila Dearybury Walcoff,

Associate Commissioner for External 

Relations.

[FR Doc. 04–24065 Filed 10–27–04; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510 and 520

New Animal Drugs; Change of Sponsor

AGENCY: Food and Drug Administration, 

HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug 

Administration (FDA) is amending the 

animal drug regulations to reflect a 

change of sponsor for three new animal 

drug applications (NADAs) from 

Sweetlix LLC to Ridley U.S. Holdings, 

Inc.

DATES: This rule is effective October 28, 

2004.

FOR FURTHER INFORMATION CONTACT:

David R. Newkirk, Center for Veterinary 

Medicine (HFV–100), Food and Drug 

Administration, 7500 Standish Pl., 

Rockville, MD 20855, 301–827–6967, email: david.newkirk@fda.gov.

SUPPLEMENTARY INFORMATION: Sweetlix 

LLC, 175 South Main St., suite 150, Salt 

Lake City, UT 84111, has informed FDA 

that it has transferred ownership of, and 

all rights and interest in, the following 

three approved NADAs to Ridley U.S. 

Holdings, Inc., 424 North Riverfront Dr., 

P.O. Box 8500, Mankato, MN 56002–

8500:

Application Number 21 CFR Section Trade Name 

NADA 033–733 520.1840 Sweetlix Bloat Guard Block